PMC:7473478 / 25985-26200 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T297","span":{"begin":187,"end":192},"obj":"Body_part"}],"attributes":[{"id":"A297","pred":"fma_id","subj":"T297","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS CAStem 9 A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg Phase 2 China 72"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T108","span":{"begin":41,"end":49},"obj":"Disease"},{"id":"T109","span":{"begin":74,"end":78},"obj":"Disease"}],"attributes":[{"id":"A108","pred":"mondo_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A109","pred":"mondo_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"}],"text":"Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS CAStem 9 A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg Phase 2 China 72"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T325","span":{"begin":91,"end":92},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T326","span":{"begin":168,"end":172},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T327","span":{"begin":187,"end":192},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS CAStem 9 A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg Phase 2 China 72"}

{"project":"LitCovid-PubTator","denotations":[{"id":"902","span":{"begin":131,"end":139},"obj":"Species"},{"id":"945","span":{"begin":41,"end":49},"obj":"Disease"},{"id":"946","span":{"begin":74,"end":78},"obj":"Disease"}],"attributes":[{"id":"A902","pred":"tao:has_database_id","subj":"902","obj":"Tax:9606"},{"id":"A945","pred":"tao:has_database_id","subj":"945","obj":"MESH:C000657245"},{"id":"A946","pred":"tao:has_database_id","subj":"946","obj":"MESH:D012128"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS CAStem 9 A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg Phase 2 China 72"}

{"project":"LitCovid-sentences","denotations":[{"id":"T231","span":{"begin":0,"end":215},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS CAStem 9 A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg Phase 2 China 72"}